Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) — Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “ Company ” or “ Helus Pharma ”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“ NSAs ”), is pleased to announce that it

Helus Pharma™ Announces US$50 Million Underwritten Offering

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) — Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “ Company ” or “ Helus Pharma ”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“ NSAs ”), is pleased to announce the

Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

– APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment – – Phase 2 HLP003 data demonstrated long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale

Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health 

Collaboration with leading mental health organization to support HLP003 Phase 3 recruitment and expand outreach in veteran communities following landmark Executive Order on breakthrough mental health treatments NEW YORK & TORONTO, April 28, 2026 (GLOBE NEWSWIRE) — Helus Pharma™ (Nasdaq: HELP)